SARASOTA, Fla., May 18, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.:
Investors may want to keep an eye on Cisco Systems Inc. (Nasdaq:CSCO), Millennium Pharmaceuticals, Inc. (Nasdaq:MLNM) and China Wireless Communications, Inc. (OTCBB:CWLC)
Tuesday's Alert:
China Wireless Communications, Inc. (OTCBB:CWLC) announced yesterday that it has renewed a technology service contract for one year with Beijing Hezhong, a professional logistic corporation located in south central business district of Beijing City. This contract expands the current dedicated fiber access services of 2 Megabits per second to include another 1 Megabit per second of capacity. China Wireless Communications, Inc., headquartered in Denver, CO provides a suite of broadband data services, including support for Internet access and Voice over IP in Beijing, China through its wholly owned subsidiary, In-Touch Communications. Go to www.chinawirelesscommunications.com and have a look at China Wireless Communications, Inc. today.
Cisco Systems Inc. (Nasdaq:CSCO). Today it was stated that IBM (NYSE:IBM) and Cisco today unveiled a broad-based initiative that will help organizations of all sizes integrate and implement converged voice, video and data systems. The new services will provide customers with a broader and more integrated portfolio of Internet Protocol (IP) Communications solutions from IBM and Cisco, yielding greater potential for cost savings and employee productivity. CSCO is currently up 0.22 (1.05%) on 2.3M shares traded
Also on the Nasdaq, making waves is Millennium Pharmaceuticals, Inc. (Nasdaq:MLNM). On Monday Millennium announced that in the final survival endpoint analysis in the phase III confirmatory APEX study comparing patients receiving VELCADE to those receiving high-dose dexamethasone, VELCADE produced a statistically significant survival benefit. The study was designed to include survival as a secondary endpoint and allowed crossover for patients experiencing disease progression on high-dose dexamethasone to receive VELCADE. Both the interim data and the final survival analysis from the APEX study will be presented on Sunday, June 6, 2004 at the upcoming American Society of Clinical Oncology (ASCO) meeting in New Orleans, LA. MLNM so far is seeing an up movement to $15.27, UP $1.71 (12.61%) on volume of 2.7M.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast.
Sign up for FREE at any of the sites above.
Contact: eLocity Inc. 941-544-3498 Thomas Clay
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is hereafter referred to as "the company." The company is expected to receive compensation for this newsletter service for China Wireless Communications, Inc. only. The compensation is one thousand dollars from a non-affiliated third party Audra Inc. Because the company is receiving compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered from the client, public filings on client, press releases and client's web site. Investors should use the information contained in this publication as a starting point for conducting additional research on the featured client in order to allow the investor to form his or her own opinion regarding the featured clients. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investment in the clients reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.